ResearchPredictors and implications of renal injury after CD19 chimeric antigen receptor T-cell therapy
ResearchDynamics of Immune Reconstitution and Impact on Outcomes across CAR-T Cell Products in Large B-cell Lymphoma
ResearchResults From First-in-Human Phase I Study of a Novel CD19-1XX Chimeric Antigen Receptor With Calibrated Signaling in Large B-Cell Lymphoma
ResearchTreatment failure patterns in early versus late introduction of CAR T-cell therapy in large B-cell lymphoma
ResearchReal-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry
ResearchRestarting teclistamab and talquetamab after prolonged dose delay may not require re-step-up dosing
ResearchAn inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphoma
ResearchMaintenance therapy with romidepsin after autologous stem-cell transplant for peripheral T-cell lymphoma
ResearchOutcomes in frail patients receiving BCMA-directed bispecific antibodies for relapsed/refractory multiple myeloma
ResearchInequalities in CAR T-cell therapy access for US patients with relapsed/refractory DLBCL: a SEER-Medicare data analysis
ResearchBone marrow and blood demonstrate distinct immune reconstitution patterns and correlations with relapse posttransplant